What is NeuCyte?
NeuCyte, Inc. is an early-stage biotechnology company dedicated to developing treatments for neurological diseases through its proprietary human iPSC-based technology platform. The company specializes in generating quality iPSC-derived neural cells for drug discovery, targeting conditions such as Alzheimer's, ALS, epilepsy, and autism. NeuCyte offers a range of services including custom cell production, assay development, and functional phenotypic assessment, aimed at optimizing CNS drug discovery. Their intended clients include biopharmaceutical companies and research institutions focused on advancing neurological treatments. The company's focus on iPSC technology positions it within the rapidly evolving field of regenerative medicine and personalized therapeutics.
How much funding has NeuCyte raised?
NeuCyte has raised a total of $7M across 2 funding rounds:
Series A
$6.7M
Debt
$350K
Series A (2018): $6.7M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in NeuCyte
PPP
Public-Private Partnership
What's next for NeuCyte?
With a significant enterprise-level funding context and a recent strategic investment, NeuCyte is poised for accelerated growth and development. The capital infusion is expected to fuel advancements in its proprietary iPSC-based technology platform, enabling the generation of higher quality neural cells for drug discovery. This strategic backing will likely support expanded research and development efforts, potentially leading to new therapeutic candidates for challenging neurological conditions like Alzheimer's, ALS, epilepsy, and autism. NeuCyte's ability to attract substantial investment signals strong market confidence in its innovative approach to CNS drug discovery and its potential to impact patient outcomes.
See full NeuCyte company page
